Olanzapine (Zyprexa Relprevv) vs Risperidone (QUAR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Olanzapine (Zyprexa Relprevv)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00088478 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.

Reported efficacy

Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)

Result source: NCT00088478

Risperidone (QUAR)

Developed by Laboratorios Farmacéuticos Rovi, S.A.

Phase 1 in Schizophreniasmall molecule
Weak signal

NCT06276361 · Phase 1 · completed

A sequential, open-label pharmacokinetic study of quarterly-injection risperidone in 58 participants, with pharmacokinetic parameters as the primary measures. The design is uncontrolled for treatment effect and no results have been posted to the registry, so this is weak evidence.

No aligned efficacy figure on record for this race.

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOlanzapine (Zyprexa Relprevv)Risperidone (QUAR)
PANSS total, change—Not posted · NCT00088491—Not posted · NCT00159770
CGI-S, change-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489—Not posted · NCT00159770
PANSS response—Not posted · NCT00088491—Not posted · NCT00159770
PSP, change—Not posted · NCT00088491—Not posted · NCT00159770
Relapse (% of patients)20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489—Not posted · NCT00159770

PANSS total, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Risperidone (QUAR)
—Not posted · NCT00159770

CGI-S, change

Olanzapine (Zyprexa Relprevv)
-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489
Risperidone (QUAR)
—Not posted · NCT00159770

PANSS response

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Risperidone (QUAR)
—Not posted · NCT00159770

PSP, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Risperidone (QUAR)
—Not posted · NCT00159770

Relapse (% of patients)

Olanzapine (Zyprexa Relprevv)
20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489
Risperidone (QUAR)
—Not posted · NCT00159770
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Risperidone (QUAR): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Olanzapine (Zyprexa Relprevv): 4 of 4 rows · Risperidone (QUAR): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlanzapine (Zyprexa Relprevv)
Dropout rate
54.9%a
NCT00320489 · Phase 3 · monotherapy
show 1 more result
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
9.8%a
NCT00320489 · Phase 3 · monotherapy
show 1 more result
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Serious AEs
9.5%a
NCT00320489 · Phase 3 · monotherapy
show 1 more result
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
weight increased 16.7%
insomnia 11%
anxiety 9.8%
NCT00320489 · Phase 3 · monotherapy
show 1 more result
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olanzapine (Zyprexa Relprevv)

Time to Discontinuation Any Reason Median 21.17 vs 22.26 Oral Olanzapine months
time to event · months
NCT00320489 · Phase 3 · monotherapy · converted to months from 644.5 days as posted
QLS Total 8.15 vs 7.24 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Component Summary 0.43 vs 0.84 Oral Olanzapine score @ 104wk
absolute change · score
Physical Score Detail Change Week 104 (n=124,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Functioning 1.35 vs 2.44 Oral Olanzapine score @ 104wk
absolute change · score
Physical Functioning Change Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Physical 10.7 vs 13.76 Oral Olanzapine score @ 104wk
absolute change · score
Role-Physical Change at Week 104 (n=130,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Bodily Pain 3.23 vs -0.6 Oral Olanzapine score @ 104wk
absolute change · score
Bodily Pain Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 General Health 2.69 vs 5.32 Oral Olanzapine score @ 104wk
absolute change · score
General Health Change at Week 104 (n=128,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Social Functioning 8.13 vs 5.1 Oral Olanzapine score @ 104wk
absolute change · score
Social Functioning Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Vitality 7.95 vs 9.01 Oral Olanzapine score @ 104wk
absolute change · score
Vitality Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Emotional 16.38 vs 17.59 Oral Olanzapine score @ 104wk
absolute change · score
Role-Emotional Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
EQ-5D 0.07 vs 0.09 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SUMD Total -0.72 vs -0.5 Oral Olanzapine score @ 104wk
absolute change · score
Total Score (Items 1-5) Change to Week 104
NCT00320489 · Phase 3 · monotherapy

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Risperidone (QUAR)'s landscape